Public market prominence The company has a history of a significant IPO with a $218M raise and is now linked to Sumitomo Pharma America, suggesting established access to capital and potential partnerships with a global pharma conglomerate for co-development or licensing opportunities.

Women health focus Strategic emphasis on uterine fibroids, endometriosis, and infertility positions potential sales opportunities with specialty clinics, OB/GYN networks, and women’s health advocacy organizations for combined diagnostics, therapeutics, and patient support services.

Prostate cancer niche Targeting prostate cancer creates a doorway to urology and oncology channels, enabling collaborations on companion diagnostics, trial enrollments, and real-world evidence initiatives with hospital systems and cancer centers.

Cost reduction needs Recent large-scale headcount reductions indicate a potential emphasis on efficiency and partnerships for cost-effective clinical development, outsourced services, and CRO/CMO collaborations to sustain R&D momentum.

Technology and security Adoption of ISO/IEC 27001, SAML, Okta, and Google Cloud signals a mature security and cloud infrastructure posture, presenting opportunities to offer cybersecurity, data governance, and compliance solutions to protect sensitive clinical data and IP.